PSA kinetics before 40 years of age

Pazeto, Cristiano Linck; Lima, Thiago Fernandes Negris; Truzzi, José Carlos; Sumita, Nairo; Sá, José de; Oliveira, Fernando R.; Glina, Sidney

doi:10.1590/S1677-5538.IBJU.2017.0710

Acessibilidade / Reportar erro

Brasil

International braz j urol

Español English

Brasil

Español English

sumário « anterior atual seguinte »

Sumário

Original Article • IBJUInt. braz j urol 44 (6) • Nov-Dec 2018 • https://doi.org/10.1590/S1677-5538.IBJU.2017.0710 copy

PSA kinetics before 40 years of age

Authorship SCIMAGO INSTITUTIONS RANKINGS

ABSTRACT

Purpose:

The baseline PSA has been proposed as a possible marker for prostate cancer. The PSA determination before 40 years seems interesting because it not suffers yet the drawbacks related to more advanced ages. Considering the scarcity of data on this topic, an analysis of PSA kinetics in this period seems interesting.

Materials and Methods:

A retrospective assay in a database of a private diagnostic center was performed from 2003 to 2016. All subjects with a PSA before 40 years were included.

Results:

92995 patients performed PSA between the ages of 21 – 39. The mean value ranged from 0.66 ng / mL (at age 22) to 0.76 ng / mL (at age 39) and the overall mean was 0.73 ng / mL. As for outliers, 3783 individuals presented a baseline PSA > 1.6 ng / mL (p95). A linear regression model showed that each year there is a PSA increase of 0.0055 ng / mL (β = 0.0055; r² = 0.0020; p < 0.001). A plateau in PSA between 23 and 32 years was found and there were only minimal variations among the ages regardless of the evaluated percentile.

Conclusion:

It was demonstrated that PSA kinetics before 40 years is a very slow and progressive phenomenon regardless of the assessed percentile. Considering our results, it could be suggested that any PSA performed in this period could represent the baseline value without significant distortions.

Keywords:
Prostate-Specific Antigen; Kinetics, Prostatic Neoplasms

Age	PSA
Age	n (%)	Mean (SD)	Median	Min	Max	Percentiles 25;75	Percentiles 90;95
21	800 (0.86)	0. 683 (0.42)	0.60	0.1	3.8	0.42; 0.82	1.2; 1.4
22	956 (1.03)	0.664 (0.37)	0.57	0.1	3.6	0.41; 0.82	1.1; 1.3
23	1112 (1.21)	0.718 (0.43)	0.62	0.1	4.0	0.44; 0.87	1.2; 1.5
24	1265 (1.36)	0.711 (0.43)	0.62	0.1	4.0	0.44; 0.86	1.2; 1.5
25	1531 (1.65)	0.720 (0.46)	0.61	0.1	3.9	0.43; 0.87	1.2; 1.5
26	1829(1.97)	0.721 (0.45)	0.62	0.1	3.8	0.43; 0.88	1.2; 1.5
27	2099(2.26)	0.717 (0.41)	0.64	0.1	3.6	0.44; 0.89	1.2; 1.5
28	2593 (2.79)	0.713 (0.44)	0.61	0.1	4.0	0.43; 0.86	1.2; 1.5
29	3106 (3.34)	0. 720 (0.44)	0.62	0.1	3.9	0.44; 0.89	1.2; 1.5
30	3106 (4.34)	0. 720 (0.44)	0.62	0.1	4.0	0.43; 0.87	1.2; 1.5
31	4459 (4.79)	0. 712 (0.44)	0.62	0.1	3.9	0.43; 0.87	1.2; 1.5
32	5293 (5.69)	0.711 (0.42)	0.61	0.1	3.9	0.43; 0.88	1.2; 1.5
33	5942 (6.39)	0. 722 (0.43)	0.62	0.1	4.0	0.44; 0.88	1.2; 1.5
34	6796 (7.31)	0. 727 (0.45)	0.62	0.1	4.0	0.44; 0.89	1.2; 1.5
35	7682 (8.26)	0. 734 (0. 44)	0.63	0.1	4.0	0.44; 0.89	1.2; 1.6
36	8579 (9.23)	0. 741 (0. 45)	0.64	0.1	4.0	0.44; 0.91	1.2; 1.5
37	9457 (10.17)	0. 748 (0. 46)	0.64	0.1	4.0	0.45; 0.91	1.3; 1.6
38	10925 (11.75)	0. 768 (0.47)	0.66	0.1	4.0	0.46; 0.94	1.3; 1.6
39	14525 (15.62)	0. 764 (0.46)	0.66	0.1	4.0	0.46; 0.93	1.3; 1.6
Total	92995 (100)	0. 737 (0.45)	0.63	0.1	4.0	0.44; 0.90	1.3; 1.6

Age	p	n
21 vs 22	0.331	1756
22 vs 23	0.004^* * post-hoc test Dunn test p<0.05.	2068
23 vs 24	0.427	2377
24 vs 25	0.344	2796
25 vs 26	0.331	3360
26 vs 27	0.171	3928
27 vs 28	0.068	4692
28 vs 29	0.173	5699
29 vs 30	0.410	6212
30 vs 31	0.257	7565
31 vs 32	0.418	9752
32 vs 33	0.072	11235
33 vs 34	0.440	12738
34 vs 35	0.040^* * post-hoc test Dunn test p<0.05.	14478
35 vs 36	0.294	16261
36 vs 37	0.090	18036
37 vs 38	0.005^* * post-hoc test Dunn test p<0.05.	20382
38 vs 39	0.490	25450

Age	n (%)		Mean (SD)		Percentiles 25;75		Percentiles 90;95
Age	Group 1	Group 2	Group 1	Group 2	Group 1	Group 2	Group 1	Group 2
21	143(0.44)	657(1.09)	0.63 (0.54)	0.69 (0.39)	0.32; 0.75	0.44; 0.85	0.99; 1.5	1.2; 1.4
22	200(0.61)	756(1.25)	0.63 (0.38)	0.67 (0.37)	0.39; 0.73	0.42; 0.84	1.4; 2.2	1.1; 1.3
23	220(0.67)	902(1.50)	0.72 (0.5)	0.71 (0.41)	0.39; 0.86	0.45; 0.88	1.2; 1.6	1.2; 1.5
24	277(0.85)	988(1.64)	0.66 (0.66)	0.72 (0.44)	0.41; 0.8	0.45; 0.87	1.2; 1.5	1.2; 1.5
25	307(0.94)	1224(2.03)	0.74 (0.51)	0.71 (0.45)	0.43; 0.87	0.42; 0.87	1.4; 1.5	1.2; 1.5
26	407(1.24)	1422(2.36)	0.66 (0.43)	0.73 (0.46)	0.40; 0.81	0.44; 0.90	1.1; 1.4	1.2; 1.5
27	496(1.52)	1603(2.66)	0.7 (0.44)	0.72 (0.4)	0.41; 0.86	0.45; 0.90	1.3; 1.5	1.2; 1.4
28	632(1.93)	1961(3.25)	0.67 (0.41)	0.72 (0.45)	0.41; 0.82	0.44; 0.88	1.1; 1.5	1.2; 1.6
29	832(2.54)	2274(3.77)	0.68 (0.45)	0.73 (0.43)	0.40; 0.82	0.45; 0.91	1.1; 1.5	1.2; 1.5
30	1129(3.45)	2907(4.82)	0.7 (0.45)	0.72 (0.44)	0.42; 0.85	0.44; 0.88	1.2; 1.5	1.3; 1.5
31	1308(4.00)	3151(5.23)	0.7 (0.46)	0.71 (0.43)	0.41; 0.84	0.44; 0.88	1.2; 1.4	1.2; 1.5
32	1638(5.01)	3655(6.06)	0.69 (0.43)	0.71 (0.41)	0.40; 0.86	0.44; 0.88	1.2; 1.5	1.2; 1.4
33	1959(5.99)	3983 (6.61)	0.71 (0.44)	0.72 (0.42)	0.43; 0.87	0.44; 0.89	1.2; 1.5	1.2; 1.5
34	2377(7.26)	4419(7.33)	0.71 (0.46)	0.73 (0.44)	0.41; 0.87	0.45; 0.91	1.2; 1.5	1.3; 1.5
35	2740(8.37)	4942(8.20)	0.72 (0.45)	0.74 (0.43)	0.43; 0.87.	0.45; 0.91	1.2; 1.6	1.3; 1.5
36	3276(10.01)	5303(8.80)	0.73 (0.47)	0.74 (0.45)	0.44; 0.90	0.45; 0.91	1.2; 1.5	1.3; 1.5
37	3839(11.73)	5618(9.32)	0.74 (0.48)	0.75 (0.44)	0.44; 0.90	0.46; 0.91	1.3; 1.6	1.3; 1.6
38	4577(13.99)	6348(10.53)	0.75 (0.48)	0.77 (0.47)	0.45; 0.91	0.46; 0.96	1.3; 1.6	1.3; 1.7
39	6364(19.45)	8161(13.54)	0.76 (0.48)	0.76 (0.45)	0.45; 0.92	0.46; 0.94	1.3; 1.6	1.3; 1.6
Total	32721 (100)	60274 (100)	0.73 (0.47)	0.74 (0.44)	0.43; 0.89	0.45; 0.91	1.3; 1.6	1.3; 1.5

Sociedade Brasileira de Urologia Rua Bambina, 153, 22251-050 Rio de Janeiro RJ Brazil, Tel. +55 21 2539-6787, Fax: +55 21 2246-4088 - Rio de Janeiro - RJ - Brazil
E-mail: brazjurol@brazjurol.com.br

Acompanhe os números deste periódico no seu leitor de RSS

[1] Correspondence address: Cristiano Linck Pazeto, MD, Departamento de Urologia, Faculdade de Medicina do ABC, Rua: Dr. Henrique Calderazo, n° 321, Paraíso, 2° andar, São Paulo, SP, 09190-615, Brasil E-mail: cristianolinckpazeto@gmail.com